It doesn't seem like there's too much momentum for healthcare stocks, says Mizuho's Jared Holz

It doesn't seem like there's too much momentum for healthcare stocks, says Mizuho's Jared HolzПодробнее

Election noise may make pharmaceutical stocks 'untenable' for investors, says Mizuho's Jared HolzПодробнее

Mizuho's Jared Holz on drug price negotiations: More difficult for industry to get better medicinesПодробнее

Medical device companies 'clear beneficiary' following Humana's warning, says Mizuho's Jared HolzПодробнее

Stick to 'stable' sectors with strong earnings, says strategistПодробнее

Will Stocks Crash? Hottest Sectors, Top Companies Not on the Market & Best 2025 Stocks ft Josh BrownПодробнее

$LABU 📉Подробнее

Mizuho's Jared Holz reacts to JPMorgan's huge obesity drug callПодробнее

Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared HolzПодробнее

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared HolzПодробнее

Obesity drug enthusiasm can continue in 2024: Mizuho's Jared HolzПодробнее

Most companies' stocks will be judged by how well they incorporate AI, says Jim CramerПодробнее

Tech plays are so strong they buoy the averages, says Jim CramerПодробнее

Bigger may be better when choosing health care stocksПодробнее

Market rally: What could keep stocks moving higher?Подробнее

Healthcare stocks under pressure as medical costs climbПодробнее

Tech stocks overvalued, but 'it's not like we've gone crazy,' says Jim CramerПодробнее

Why investors should avoid healthcare stocksПодробнее

Stocks Advance as Nvidia Closes at All-Time High | Bloomberg: The Close 01/06/2025Подробнее

Mizuho's Jared Holz on finding opportunities in the biotech spaceПодробнее